Wu Shi-wu, Yu Lan, Zhou Lei, Cheng Ze-nong, Tao Yi-sheng
Department of Pathology, the First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
Zhonghua Zhong Liu Za Zhi. 2013 Feb;35(2):124-8. doi: 10.3760/cma.j.issn.0253-3766.2013.02.010.
To study the expression of galectin 3 (Gal-3) and CD82/KAI1 proteins in non-small cell lung cancer (NSCLC) and the correlation between their expression and clinical significance.
The expression of Gal-3 and CD82/KAI1 proteins was detected by immunohistochemistry in 160 specimens of NSCLC and 20 specimens of normal lung tissue.
The positive rates of Gal-3 and CD82/KAI1 proteins in the NSCLC were 63.8% and 37.5%, respectively, the positive rates of Gal-3 and CD82/KAI1 proteins in the normal lung tissue were 25.0% and 95.0%, respectively, and there was a significant difference between the two groups (P < 0.01). The expression of Gal-3 and CD82/KAI1 proteins was significantly correlated with the grade of tumor, lymph node metastasis, and pathological-TNM stages (all P < 0.05). Spearman analysis showed that there was a negative correlation between expressions of Gal-3 and CD82/KAI1 in NSCLC (r = -0.732, P < 0.01). Overexpression of Gal-3 and low expression of CD82/KAI1 were related to poor prognosis: the survival rate was significantly lower in the positive Gal-3 group (survival time: 23.0 ± 17.5 months) than that in the negative group (survival time: 71.6 ± 21.6 months) (P < 0.01). The survival rates of the CD82/KAI1-positive group (survival time: 72.5 ± 19.5 months) and CD82/KAI1-negative group (survival time: 21.6 ± 16.1 months) were significantly different (P < 0.01). Multivariate analysis indicated that pTNM stage and positive expression of Gal-3 and CD82/KAI1 are independent prognostic factors of NSCLC (P < 0.01).
The expression of Gal-3 and CD82/KAI1 may be related to the initiation, development and metastasis of NSCLC. Combined detection of Gal-3 and CD82/KAI1 has an important role in predicting the progression and prognosis of NSCLC.
研究半乳糖凝集素3（Gal-3）和CD82/KAI1蛋白在非小细胞肺癌（NSCLC）中的表达情况及其表达与临床意义之间的相关性。
采用免疫组织化学法检测160例NSCLC标本和20例正常肺组织标本中Gal-3和CD82/KAI1蛋白的表达。
NSCLC中Gal-3和CD82/KAI1蛋白的阳性率分别为63.8%和37.5%，正常肺组织中Gal-3和CD82/KAI1蛋白的阳性率分别为25.0%和95.0%，两组间差异有统计学意义（P < 0.01）。Gal-3和CD82/KAI1蛋白的表达与肿瘤分级、淋巴结转移及病理TNM分期均显著相关（均P < 0.05）。Spearman分析显示，NSCLC中Gal-3与CD82/KAI1的表达呈负相关（r = -0.732，P < 0.01）。Gal-3高表达和CD82/KAI1低表达与预后不良相关：Gal-3阳性组的生存率（生存时间：23.0 ± 17.5个月）显著低于阴性组（生存时间：71.6 ± 21.6个月）（P < 0.01）。CD82/KAI1阳性组（生存时间：72.5 ± 19.5个月）和CD82/KAI1阴性组（生存时间：21.6 ± 16.1个月）的生存率差异有统计学意义（P < 0.01）。多因素分析表明，pTNM分期以及Gal-3和CD82/KAI1的阳性表达是NSCLC的独立预后因素（P < 0.01）。
Gal-3和CD82/KAI1的表达可能与NSCLC的发生、发展及转移有关。联合检测Gal-3和CD82/KAI1对预测NSCLC的进展及预后具有重要作用。
